144 related articles for article (PubMed ID: 10100921)
21. Engineered beta-cells secreting dipeptidyl peptidase IV-resistant glucagon-like peptide-1 show enhanced glucose-responsiveness.
Islam MS; Rahman SA; Mirzaei Z; Islam KB
Life Sci; 2005 Jan; 76(11):1239-48. PubMed ID: 15642594
[TBL] [Abstract][Full Text] [Related]
22. A kinetic study of glucagon-like peptide-1 and glucagon-like peptide-2 truncation by dipeptidyl peptidase IV, in vitro.
Lambeir AM; Proost P; Scharpé S; De Meester I
Biochem Pharmacol; 2002 Dec; 64(12):1753-6. PubMed ID: 12445864
[TBL] [Abstract][Full Text] [Related]
23. Development of glucagon-like peptide-1-based pharmaceuticals as therapeutic agents for the treatment of diabetes.
Drucker DJ
Curr Pharm Des; 2001 Sep; 7(14):1399-412. PubMed ID: 11472275
[TBL] [Abstract][Full Text] [Related]
24. Glucagon-like peptides.
Drucker DJ
Diabetes; 1998 Feb; 47(2):159-69. PubMed ID: 9519708
[TBL] [Abstract][Full Text] [Related]
25. GLP-1/GIP chimeric peptides define the structural requirements for specific ligand-receptor interaction of GLP-1.
Gallwitz B; Witt M; Morys-Wortmann C; Fölsch UR; Schmidt WE
Regul Pept; 1996 May; 63(1):17-22. PubMed ID: 8795084
[TBL] [Abstract][Full Text] [Related]
26. Structure-activity relationships of glucagon-like peptide-1(7-36)amide: insulinotropic activities in perfused rat pancreases, and receptor binding and cyclic AMP production in RINm5F cells.
Watanabe Y; Kawai K; Ohashi S; Yokota C; Suzuki S; Yamashita K
J Endocrinol; 1994 Jan; 140(1):45-52. PubMed ID: 8138751
[TBL] [Abstract][Full Text] [Related]
27. Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.
Holst JJ
Expert Opin Emerg Drugs; 2004 May; 9(1):155-66. PubMed ID: 15155141
[TBL] [Abstract][Full Text] [Related]
28. Long-lasting antidiabetic effect of a dipeptidyl peptidase IV-resistant analog of glucagon-like peptide-1.
Burcelin R; Dolci W; Thorens B
Metabolism; 1999 Feb; 48(2):252-8. PubMed ID: 10024091
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes.
Holst JJ; Deacon CF
Diabetes; 1998 Nov; 47(11):1663-70. PubMed ID: 9792533
[TBL] [Abstract][Full Text] [Related]
30. The positive charge of the imidazole side chain of histidine7 is crucial for GLP-1 action.
Hareter A; Hoffmann E; Bode HP; Göke B; Göke R
Endocr J; 1997 Oct; 44(5):701-5. PubMed ID: 9466326
[TBL] [Abstract][Full Text] [Related]
31. A synthetic glucagon-like peptide-1 analog with improved plasma stability.
Ritzel U; Leonhardt U; Ottleben M; Rühmann A; Eckart K; Spiess J; Ramadori G
J Endocrinol; 1998 Oct; 159(1):93-102. PubMed ID: 9795346
[TBL] [Abstract][Full Text] [Related]
32. Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects.
Meier JJ; Nauck MA; Kranz D; Holst JJ; Deacon CF; Gaeckler D; Schmidt WE; Gallwitz B
Diabetes; 2004 Mar; 53(3):654-62. PubMed ID: 14988249
[TBL] [Abstract][Full Text] [Related]
33. Comparison of stability, cellular, glucose-lowering and appetite supressing effects of oxyntomodulin analogues modified at the N-terminus.
Lynch AM; Pathak N; Flatt YE; Gault VA; O'Harte FP; Irwin N; Flatt PR
Eur J Pharmacol; 2014 Nov; 743():69-78. PubMed ID: 25246014
[TBL] [Abstract][Full Text] [Related]
34. A model for receptor-peptide binding at the glucagon-like peptide-1 (GLP-1) receptor through the analysis of truncated ligands and receptors.
Al-Sabah S; Donnelly D
Br J Pharmacol; 2003 Sep; 140(2):339-46. PubMed ID: 12970080
[TBL] [Abstract][Full Text] [Related]
35. Glucagon-like peptide-1 improves insulin and proinsulin binding on RINm5F cells and human monocytes.
Ebinger M; Jehle DR; Fussgaenger RD; Fehmann HC; Jehle PM
Am J Physiol Endocrinol Metab; 2000 Jul; 279(1):E88-94. PubMed ID: 10893327
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and bioactivity evaluation of dipeptidyl peptidase IV resistant glucagon-like peptide-1 analogues.
Zhou J; Ni S; Zhang H; Qian H; Chi Y; Huang W; Yu L; Hu X; Chen W
Protein Pept Lett; 2010 Oct; 17(10):1290-5. PubMed ID: 20594158
[TBL] [Abstract][Full Text] [Related]
37. Glucagon-like peptide 1 (GLP-1) secretion and plasma dipeptidyl peptidase IV (DPP-IV) activity in morbidly obese patients undergoing biliopancreatic diversion.
Lugari R; Dei Cas A; Ugolotti D; Barilli AL; Camellini C; Ganzerla GC; Luciani A; Salerni B; Mittenperger F; Nodari S; Gnudi A; Zandomeneghi R
Horm Metab Res; 2004 Feb; 36(2):111-5. PubMed ID: 15002062
[TBL] [Abstract][Full Text] [Related]
38. Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes.
Mest HJ; Mentlein R
Diabetologia; 2005 Apr; 48(4):616-20. PubMed ID: 15770466
[TBL] [Abstract][Full Text] [Related]
39. Lys9 for Glu9 substitution in glucagon-like peptide-1(7-36)amide confers dipeptidylpeptidase IV resistance with cellular and metabolic actions similar to those of established antagonists glucagon-like peptide-1(9-36)amide and exendin (9-39).
Green BD; Mooney MH; Gault VA; Irwin N; Bailey CJ; Harriott P; Greer B; Flatt PR; O'Harte FP
Metabolism; 2004 Feb; 53(2):252-9. PubMed ID: 14767880
[TBL] [Abstract][Full Text] [Related]
40. Enhancing incretin action for the treatment of type 2 diabetes.
Drucker DJ
Diabetes Care; 2003 Oct; 26(10):2929-40. PubMed ID: 14514604
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
